Dln Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
- Paid Up Capital ₹ 1.50 Cr
- Company Age 2 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.30 Cr
About Dln Drugs
Dln Drugs Private Limited (DDPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 June 2022 (Two years and seven months 27 days old ). Its registered office is in Khorda, Odisha, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹4.30 Cr.
Pradeep Pani and Sambit Karmakar serve as directors at the Company.
Company Details
-
Location
Khorda, Odisha, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909OR2022PTC040047
-
Company No.
040047
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Jun 2022
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Dln Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradeep Pani
|
Director | 21-Jun-2022 | Current |
| Sambit Karmakar | Director | 01-Sep-2022 | Current |
Financial Performance of Dln Drugs.
Dln Drugs Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dln Drugs?
Unlock access to Dln Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Bd Medisys Private LimitedPradeep Pani is a mutual person
Charges (Loans)
₹4.30 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 4.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Nov 2022 | State Bank Of India | ₹4.30 Cr | Open |
How Many Employees Work at Dln Drugs?
Dln Drugs has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dln Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dln Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
